Werewolf Therapeutics (HOWL) risk factors
Item 1A of every Werewolf Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors94 risks13 new2 dropped14 reworded
Werewolf Therapeutics faces a going concern warning with $57.1 million in cash and substantial operating losses.
Filed Mar 27, 2026 - FY2024 10-K risk factors83 risks
This biopharmaceutical company faces substantial clinical development and financial risks typical of an early-stage enterprise without approved products or commercial revenue. The company relies heavily on its unproven PREDATOR platform and lead INDUKINE candidates, WTX-124 and WTX-330, to generate future value. Operations depend significantly on third-party contract manufacturing, patent protection, and ongoing capital raises while carrying a term loan facility.
Filed Mar 11, 2025